NCT06865898进行中（未招募）不适用
Plasma Proteomics Study of End-Stage Liver Disease Patients Based on Olink Technology
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 58
- 试验地点
- 1
- 主要终点
- Mortality
研究概览
简要总结
Exploring Early Biomarkers of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure Using Olink Proteomics
详细描述
The rationale for this study is that, with the changing epidemiology of liver diseases, traditional diagnostic methods are no longer sufficient to meet clinical needs. Olink technology, however, offers the potential to discover novel biomarkers. By comparing the plasma proteomic profiles of patients with cirrhosis and liver failure, we aim to identify clinically significant markers. This not only has the potential to enhance early diagnostic capabilities but also provides an important basis for personalized treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HBV-LC patients were diagnosed based on previous liver biopsy results or clinical evidence and laboratory tests of previous decompensation for more than three months, including ascites, gastrointestinal bleeding, infection, hepatic encephalopathy, or a combination of these symptoms, endoscopic examination (esophageal and gastric varices), and radiological imaging of portal hypertension and/or liver nodules.
- •The inclusion criteria for HBV-ACHD patients in this study were based on patients with chronic stable decompensated cirrhosis who experienced an acute decompensation within three months. The reference criteria for acute decompensation in the HBV-ACHD group were as follows: patients with previously diagnosed decompensated cirrhosis presenting with a high level of jaundice (total bilirubin ≥5 mg/dL) HBV-ACLF was categorized into three grades based on the severity of the condition. The inclusion criteria for HBV-ACLF-1 were as follows: patients presenting with liver failure alone with an international normalized ratio (INR) ≥1.5 and/or kidney dysfunction and/or hepatic encephalopathy (HE) grade I or II. HBV-ACLF-2 was defined by dual-organ system failure, while HBV-ACLF-3 was characterized by failure involving three or more organ systems.
排除标准
- •Associated with other types of hepatitis virus infection or HIV infection, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury; ② Suffering from primary liver cancer or severe heart, digestive, lung, kidney, neurological and psychiatric diseases; ③ Patients with incomplete data and patients unable to participate in the experiment.
结局指标
主要结局
Mortality
时间窗: 28 days, 90 days
次要结局
- Differential protein levels(28 days, 90 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in ChinaLiver Failure, Acute on ChronicLiver InjuryNCT03281265Nanfang Hospital, Southern Medical University1,178
Unknown
不适用
Platelet Transfusion in HBV-related acute-on Chronic Liver FailureAcute-On-Chronic Liver FailureNCT03713489Nanfang Hospital, Southern Medical University20
进行中（未招募）
不适用
Biomarkers in Liver FailureAcute Liver InjuryAcute Liver FailureAcute on Chronic Hepatic FailureNCT02833064University of Edinburgh200
已完成
4 期
Does Extra-High Dose Hepatitis B Vaccination Confer Longer Serological Protection in Peritoneal Dialysis Patients?Peritoneal DialysisRenal Disease, End-StageNCT00125775Chinese University of Hong Kong130
已完成
不适用
Prediction Model Based on Computed Tomography Liver Volume for the Short-term Mortality in Hepatitis B Related Acute-on-ChronicHepatitis B, ChronicAcute-on-Chronic Liver FailureNCT03977857First Affiliated Hospital Xi'an Jiaotong University486